Introduction: Nitroglycerin (NTG) is thought to relieve ischemia by increasing coronary blood flow (CBF) via dilation of conductance vessels or from collaterals, or by its effects on hamodynamics. We have shown, however, that increases in hyperemic CBF are limited mainly by capillary or myocardial vascular resistance (MVR), which depends on blood viscosity. We therefore hypothesized that enhancement of nutrient blood flow to ischemic zones during NTG are secondary not to decreases in stenosis resistance (SR) or collateral flow, but to reduced blood viscosity.
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Prshospital Fibrinolysis: Is It Safe, Feasible, and Efficient in a Large Urban North American Center? Background: Although thrombolyfic treatment is associated with a significant reduction in the risk of death after acute myocardial infarction (MI), it is also associated with a significant incidence of hemorrhagic complications and with the short-tarm recurrence of angina and MI. A possible contdbufion to these events is the hamostatic derangement elicited by fibrinolytic agents which, however, may differ from agent to agent. The aim of this study was to compare the hemostatic effects of tenecteplase (TNK-tPA), altaplase (rt-PA) and streptokinase (SK) by measuring the plasma concentrations of procoagulant and fibrinolytic-activity markers before and after thrombolysis. Methods: We assessed the levels of thrombin-antithrombin (TAT), prothrombin fragment F1+2, plasminogen activator inhibitor-1 (PAl-l) and plasmin-antiplasmin (PAP) in 45 patients with acute MI randomized to receive either TNK-tPA (30-50 mg weight adjusted in a single bolus), rt-PA (100 mg over 90 minutes), or SK (1,500,000 IU over 1 hour), in addition to heparin (8001U/h) and aspirin. Blood samples were taken on admission (prior to randomization), and after 2, 6 and 24 hours from the start of thrombolysis. Results: A significant increase in TAT levels from admission values was observed at 2h in patients treated with SK (p<0.05 Background: Mortality rates in acute MI trial are low, and recurrent MI (re MI) or death/re MI have emerged as a critical endpoints. However, many of these trials used investigator assessment of reMI at the clinical site rather than clinical event committee (CEC) adjudication. We hypothesized that site assessed reMI would be more frequent than CEC adjudicated reMI, and that mortality would be higher in patients with a CEC adjudicated reMI. Methods: Data were drawn from the TIMI 9A, 9B and 14 acute MI trials. All pts with a site assessed MI and a CEC review of the reMI were included in the substudy (n=534), There were 573 reMIs in the study (total greater due to multiple reMIs in some pts). Results: ReMI was confirmed by adjudication in 40.1% (220/548) of site assessed reMIs. The CEC confirmed 25 reMIs the sites did not identify. Mortality by 30 days was higher in pts with a CEC confirmed reMI than in pts with a reMI assessed by the site only (13.27% vs 7.72%, p=0.04) (Figure) . Pts who were not classified as an MI by either site or the CEC of reMI had lower mortality (5.32%) than those with a CEC reMI (p<0,001) and only trended lower compared with those with a site reMI only (p=0,078). Conclusion: CEC review of reMI results in lower rates of reMI compared with clinical site assessment. The 30 day mortality rate associated with a CEC confirmed reMI was higher than in pts with no MI, while there was only a trend for mortality for site assessed reMI to differ from no MI. 
